ReviewElectrolyte & blood pressure : E & BP2013
Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension.
Review in Electrolyte & blood pressure : E & BP, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- A Systematic Review of Publications on the Associations Between Sleep Architecture and Arterial Hypertension.Medical science monitor : international medical journal of experimental and clinical research · 2023Pooled it
- Pooled it
- Hemp seed protein and its hydrolysate compared with casein protein consumption in adults with hypertension: a double-blind crossover study.The American journal of clinical nutrition · 2024Trial
- Salivary Aldosterone as a Biomarker for Obstructive Sleep Apnea: Diagnostic Performance and the Moderating Role of Mean Arterial Pressure-A Cross-Sectional Study.Clocks & sleep · 2026Article
- Exploring the genetic basis of essential hypertension: association with AGT gene variants in an Iranian population.BMC genomics · 2025Article
- Article
- Review of the Protective Mechanism of Curcumin on Cardiovascular Disease.Drug design, development and therapy · 2024Review
- Dipeptidyl-peptidase 3 and IL-6: potential biomarkers for diagnostics in COVID-19 and association with pulmonary infiltrates.Clinical and experimental medicine · 2023Observational
- ACE2 in male genitourinary and endocrine systems: Does COVID-19 really affect these systems?Histology and histopathology · 2023Review
- Whole exome sequencing identifies a rare variant in MAS1 gene in a subject with lethal COVID-19.Gene reports · 2022Article
- Potential therapeutic effects and applications of Eucommiae Folium in secondary hypertension.Journal of pharmaceutical analysis · 2022Review
- Positive Effect of a Pea-Clam Two-Peptide Composite on Hypertension and Organ Protection in Spontaneously Hypertensive Rats.Nutrients · 2022Article
- Effect of calcifediol supplementation on renin-angiotensin-aldosterone system mediators in dogs with chronic kidney disease.Journal of veterinary internal medicine · 2022Article
- Renal Denervation Influences Angiotensin II Types 1 and 2 Receptors.International journal of nephrology · 2022Review
- Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.Internal and emergency medicine · 2021Article
- Article
- ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease.Clinical science (London, England : 1979) · 2021Review
- Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.Frontiers in endocrinology · 2021Review
- Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.Emerging microbes & infections · 2020Article
- Antihypertensive effects of the hydro-ethanol extract of Senecio serratuloides DC in rats.BMC complementary and alternative medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activation of renin-angiotensin-aldosterine system(RAAS) is one of the main pathogenesis of hypertension. All the components of RAAS are present in the kidneys at higher concentrations compared to plasma levels, and intrarenal formation of angiotensin II (Ang II) is independent of the systemic RAAS. There are some unique features in intrarenal RAAS compared to systemic RAAS. Unlike JG cells where Ang II inhibits renin release via the AngII type 1 (AT1) receptor by negative feedback, in the collecting duct Ang II stimulates renin expression via the AT1 receptor. Upregulated renin produced in the distal nephron may be able to support continued intrarenal Ang II formation leading to amplification or maintenance of the hypertensive state.The recently discovered angiotensin-converting enzyme-related carboxypeptidase 2 (ACE2)-Angiotensin-(1-7) Ang-(1-7)-Mas receptor axis has an opposing function to that of the ACE-Ang II-AT1 receptor axis.The ACE2 deficiency was associated with an increase in blood pressure, and ACE2 knockout mice have highlighted hypertensive response to Ang II infusion associated with exaggerated accumulation of Ang II in the kidney. Recently, several numbers of patients have been evaluated as the activators of ACE2-Ang-(1-7)-Mas receptor axis, which can be divided into two main classes: aimed to increase the activity of ACE2, and directed to stimulate the Ang-(1-7) receptor Mas. In order to investigate new targets for hypertension and kidney disease, further research on the function of the ACE-Ang-(1-7)-Mas receptor axis is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.